论文部分内容阅读
为探讨不同类型脑缺血患者急性期血小板活化指标α—颗粒膜糖蛋白(CD62p)和溶酶体膜糖蛋白(CD63)的变化,采用流式细胞术测定123例脑缺血患者CD62p、CD63。结果发现CD62p、CD63依次:脑血栓形成(8.03％±8.84％、11.30％±12.62％)、多发腔隙性脑梗死(8.48％±9.52％、7.91％±5.52％)>单发腔隙性脑梗死(1.85％±2.70％、3.41％±2.88％)≥脑栓塞(1.13％±0.70％、4.96％±6.57％)、椎基底动脉供血不足(1.11％±0.91％、3.77％±3.47％)、正常健康人(0.80％±0.68％、2.81％±1.29％)。脑梗死患者CD62p、CD63与梗死面积、血小板计数和平均体积无关,提示CD62p、CD63测定有助于脑血栓形成与脑栓塞的临床鉴别诊断,可能CD63作为血小板活化指标较CD62p更为敏感。
To investigate the changes of platelet-activating glycoprotein (CD62p) and lysosomal membrane glycoprotein (CD63) in acute ischemic stroke patients with different types of cerebral ischemia, the expression of CD62p, CD63 . The results showed that CD62p and CD63 were as follows: cerebral thrombosis (8.03% ± 8.84%, 11.30% ± 12.62%), multiple lacunar infarction (8.48% ± 9.52%, 7.91% ± 5.52% Cerebral infarction (1.13% ± 0.70%, 4.96% ± 6.57%), vertebrobasilar insufficiency (1.11% ± 0.91%, 3.77% ± 3.47% Normal healthy people (0.80% ± 0.68%, 2.81% ± 1.29%). CD62p and CD63 in patients with cerebral infarction have no relation with infarction area, platelet count and average volume, suggesting that CD62p and CD63 are helpful for the differential diagnosis of cerebral thrombosis and cerebral embolism. CD63 may be more sensitive than CD62p as an index of platelet activation.